News from the European Foundation for Clinical Nanomedicine (CLINAM)
-
Beat Löffler
Dear Readers
The next Summit of CLINAM is coming soon: many aspects of this year’s conference are new. However, one thing is sure for the days from June 28 to July 1: it will be a conference of true debate. It will include ample time for questions and lively debates to discuss science in depth in small groups in the lounge.
One hundred and thirty presentations will be given from all fields of all stakeholders. New this year are the many collaborators at CLINAM who support the neutral platform of the non-profit CLINAM Foundation, which foster the development of Nanomedicine and Targeted Medicine. These are shown with their logos on the first page of the program.
During the last 8 years, the CLINAM SUMMIT has become a worldwide interdisciplinary Nanomedicine platform with more than 500 participants from 42 countries joining in 2014. CLINAM’s major goal is to support the development and application of Nanomedicine and Targeted Medicine from basic research all the way to the clinics for the benefit of the patient and humankind.
The CLINAM Summit has achieved a unique position in bringing together all stakeholders in the fields of Nanomedicine and Targeted Medicine, including regulatory authorities from all continents, clinicians, researchers and industrial innovators. The CLINAM Summit has established itself as a valuable interaction venue to launch collaboration, get new ideas and learn about novel methodologies and technologies as well as novel projects, including numerous EU-wide efforts, in Nanomedicine and Targeted Medicine. The field represents one of the most exciting and promising arenas for novel technologies, assisting in combating devastating diseases in developing and industrialized countries and in generating novel concepts for addressing the challenges associated with demographic changes in the European and global society.
Nanomedicine and Targeted Medicine are the catalyst disciplines for developing diagnostics and treatments accounting for the nanoscale, molecular and cellular origins of disease and one of the enabling disciplines for the Knowledge-Based Medicine of tomorrow. The pathway from the innovative idea to the application, the development, regulatory approval and commercialization of nanomedical drugs is complex and first and foremost requires understanding the cause of the disease. The nature of nano-drugs and their use require a high level of knowledge in many other disciplines including physics, chemistry, pharmacy biology, engineering and nanotechnology. Transdisciplinary debate is a “must”. The translation process from research findings to applications in Nanomedicine and Targeted Medicine has been well developed and is now on the agenda of the global players in the pharmaceutical industry. The decision makers in pharmaceutical companies are beginning to appreciate the quality and potential of Nanomedicine and Targeted Medicine for significantly increasing the output of diagnostics and therapeutic products, which are less invasive and possess reduced side effects.
By bringing the relevant stakeholders together, the CLINAM Summit has achieved an active promoting role in this process. Over the next decades, medicine will experience a transformation to personalized diagnosis and treatment, taking the individual aspects of the patient and his/her disease into consideration. High resolution profiling techniques have played a key role and have been made less expensive by Nanomedicine. The CLINAM Summit offers excellent opportunities for a large number of worldwide organizations, which are working towards this goal, to exchange expertise and to launch joint ventures for further acceleration of the process. It goes without saying that we would be delighted to welcome you in Basel again!
Sincere regards
Dr. med. h.c. Beat Löffler, MA
CEO of the European Foundation for Clinical Nanomedicine
E-mail: loeffler@clinam.org
©2015 by De Gruyter
Articles in the same Issue
- Frontmatter
- In this issue
- News
- News from the European Foundation for Clinical Nanomedicine (CLINAM)
- What’s up in nanomedicine?
- Special Section Nanosafety
- Guest Editorial
- Sizing up the safety of nanomaterials
- Essay
- Keeping it small: towards a molecular definition of nanotoxicology
- Reviews
- The bio-corona and its impact on nanomaterial toxicity
- In vitro-ex vivo model systems for nanosafety assessment
- Meeting Report
- Nanosafety forum for young scientists: a meeting report
- Short Communication
- Nanomedicines in the European translational process
- Special Section CARPA Part 2
- Guest Editorial
- Complement activation-related pseudoallergy: an innate response to nanomedicines acting as pseudo-viruses
- Reviews
- Exosomes: potential model for complement-stealth delivery systems
- Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols
- Mini Review
- Blood cell changes in complement activation-related pseudoallergy
- Short Communications
- Membrane attack complex formation on a supported lipid bilayer: initial steps towards a CARPA predictor nanodevice
- Paradoxical rise of hemolytic complement in the blood of mice during zymosan- and liposome-induced CARPA: a pilot study
- Commentary
- Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system
Articles in the same Issue
- Frontmatter
- In this issue
- News
- News from the European Foundation for Clinical Nanomedicine (CLINAM)
- What’s up in nanomedicine?
- Special Section Nanosafety
- Guest Editorial
- Sizing up the safety of nanomaterials
- Essay
- Keeping it small: towards a molecular definition of nanotoxicology
- Reviews
- The bio-corona and its impact on nanomaterial toxicity
- In vitro-ex vivo model systems for nanosafety assessment
- Meeting Report
- Nanosafety forum for young scientists: a meeting report
- Short Communication
- Nanomedicines in the European translational process
- Special Section CARPA Part 2
- Guest Editorial
- Complement activation-related pseudoallergy: an innate response to nanomedicines acting as pseudo-viruses
- Reviews
- Exosomes: potential model for complement-stealth delivery systems
- Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols
- Mini Review
- Blood cell changes in complement activation-related pseudoallergy
- Short Communications
- Membrane attack complex formation on a supported lipid bilayer: initial steps towards a CARPA predictor nanodevice
- Paradoxical rise of hemolytic complement in the blood of mice during zymosan- and liposome-induced CARPA: a pilot study
- Commentary
- Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system
